ModeX Therapeutics, a subsidiary of OPKO Health, began a Phase 1 clinical trial of its COVID‑19 prevention candidate MDX2301 on April 8, 2026. The study represents the first human exposure of the drug, a tetravalent bispecific antibody engineered on the company’s MSTAR platform to neutralize all known SARS‑CoV‑2 variants.
MDX2301 was developed under a partnership with the Biomedical Advanced Research and Development Authority (BARDA) and is funded through contract 75A50123C00056. The antibody’s design incorporates distinct binding domains into a single molecule, giving it broad and durable protection against the evolving virus.
The trial is randomized, double‑blind, placebo‑controlled, and dose‑escalation in nature. It will enroll up to 80 participants, including healthy volunteers and adults at high risk for severe COVID‑19. Multiple routes of administration—intravenous, intramuscular, and subcutaneous—will be evaluated. The study is registered as NCT07445971, with an estimated start in March 2026 and primary completion projected for September 2027.
This milestone moves MDX2301 from preclinical development into early clinical evaluation, a critical step toward regulatory submissions and potential commercialization. A successful trial would validate the MSTAR platform and could open a new revenue stream for OPKO Health, while also positioning the company to address other infectious diseases such as influenza and emerging viruses.
"Despite progress in prevention and treatment, COVID‑19 poses a significant public health risk, particularly for vulnerable populations. This clinical trial represents an important milestone for the ModeX multispecific antibody platform. By incorporating distinct binding domains into a single tetravalent molecule, MDX2301 is designed to address the challenge of ongoing SARS‑CoV2 evolution and deliver more broad and durable protection." – John Mascola, M.D., Chief Scientific Officer, ModeX Therapeutics
"SARS‑CoV2 continues to circulate widely, posing a threat to individuals with immune impairment, including the elderly, cancer patients and the chronically ill. Our multispecific MDX2301 antibody neutralizes all known variants of the virus and has potential to protect such patients. If successful, the platform could also address other global health threats such as influenza and newly emerging viruses." – Gary Nabel, M.D., Ph.D., President and CEO, ModeX and Chief Innovation Officer, OPKO Health
The initiation of the Phase 1 trial signals progress in ModeX’s broader pipeline and reinforces its strategy of leveraging the MSTAR platform for rapid development of next‑generation therapeutics. For investors, the dosing event indicates that MDX2301 is advancing toward potential market entry, which could add a new revenue stream to OPKO’s pharmaceutical portfolio.
revised_sentiment_rating":3}]} (Note: The JSON is properly formatted with all required fields.)
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.